Timing of Medicaid Enrollment, Late-Stage Breast Cancer Diagnosis, Treatment Delays, and Mortality

Evaline Xie,Graham A Colditz,Min Lian,Tracy Greever-Rice,Chester Schmaltz,Jill Lucht,Ying Liu

DOI: https://doi.org/10.1093/jncics/pkac031

2022-04-19

JNCI Cancer Spectrum

Abstract:Abstract Background Disrupted and delayed Medicaid coverage has been consistently associated with lower rates of cancer screening and early-stage cancer diagnosis than continuous coverage. However, the relationships between Medicaid coverage timing, breast cancer treatment delays, and survival are less clear. Methods Using the linked Missouri Cancer Registry-Medicaid claims data, we identified 4,583 women diagnosed with breast cancer between 2007 and 2016. We used logistic regression to estimate odds ratios (ORs) of late-stage diagnosis and treatment delays for pre-diagnosis (>30 days, >90 days, and >1 year before diagnosis) versus peri-diagnosis enrollment. Cox proportional hazards models were used to estimate the hazard ratio (HR) of breast cancer-specific mortality for pre- versus post-diagnosis enrollment. Results Patients enrolled in Medicaid >30 days before diagnosis were less likely to be diagnosed at a late stage compared to those enrolled in Medicaid peri-diagnosis (OR = 0.69, 95% CI = 0.60–0.79). This result persisted using enrollment 90-day (OR = 0.64, 95% CI = 0.56–0.74) and 1-year thresholds (OR = 0.55, 95% CI = 0.47–0.65). We did not observe a difference in the likelihood of treatment delays between the two groups. After adjustment for sociodemographic factors, there was no significant difference in the risk of breast cancer-mortality for patients enrolled >30 days pre-diagnosis relative to patients enrolled peri-diagnosis (HR = 0.98, 95% CI = 0.83–1.14), but a lower risk was observed for patients enrolled pre-diagnosis when using 90 days (HR = 0.85, 95% CI = 0.72–0.999) or 1 year (HR = 0.79, 95% CI = 0.66–0.96) as the threshold. Conclusions Women with breast cancer who enroll in Medicaid earlier may benefit from earlier diagnoses, but only longer-term enrollment may have survival benefits.